Delving into the Latest Updates on AVI-4065 with Synapse

Overview

Basic Info

Drug Type

ASO

Synonyms

AVI 4065

Target-

Action

inhibitors

Mechanism

Virus replication inhibitors

Therapeutic Areas

Infectious DiseasesDigestive System DisordersNervous System Diseases

Active Indication-

Inactive Indication

EncephalitisHepatitis C

Originator Organization

Sarepta Therapeutics, Inc.

Active Organization-

Inactive Organization

Sarepta Therapeutics, Inc.

License Organization-

Drug Highest PhaseDiscontinuedPhase 1/2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

AVI-4020 Injection, a phosphorodiamidate Morpholino oligomer (PMO), was found to cross the blood-brain barrier during a study of patients with presumptive West Nile virus disease. AVI-4065, which was designed to target HCV, is also a PMO; its ability to cross the blood-brain barrier is unknown. In this study, a single dose of AVI-4065 will be subcutaneously injected, and samples collected to determine if this drug crosses the blood-brain barrier. If it does, then additional investigations could be performed in people with severe forms of HCV disease in which the brain is affected.

Start Date31 Aug 2006

Sponsor / Collaborator

Sarepta Therapeutics, Inc.

NCT00229749

/ TerminatedPhase 1/2

Exploratory Study of AVI-4065 Injection to Design Therapeutic Dosing for Chronic Active HCV Patients

Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate. AVI-4065 Injection is a new drug designed to prevent the virus from reproducing in the body. We tested this drug in healthy adult volunteers to optimize the dosing regimen, and are now proceeding in adult patients with chronic active hepatitis C infections. Patients who have the disease and who have had treatment but without success, will be recruited for the study.
The treatment of HCV patients initially consisted of subcutaneous injections given twice a day for 14-days. Treatment arms of 28 days, twice or three-times per day have been added.

Start Date31 Aug 2005

Sponsor / Collaborator

Sarepta Therapeutics, Inc.

100 Clinical Results associated with AVI-4065

Login to view more data

100 Translational Medicine associated with AVI-4065

Login to view more data

100 Patents (Medical) associated with AVI-4065

Login to view more data

100 Deals associated with AVI-4065

Login to view more data